ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Your message to azzymaa

<< Previous

Bullboard Posts

Next >>

Comment by azzymaaon Jan 28, 2022 3:14pm

90 Views

Post# 34372701

RE:RE:RE:Your message to azzymaa

Obviously not enough DD! Going back and checking this Forum it seems to be a bunch of Bag Holders crying about their Losses and crying about the CEO.
Wasn't there suppose to be a some sort of Serology Covid 19 Test like Years ago? Was the CEO lying about this? Someone mentioned that they have scraped that test all together.
How does upper management justify taking half a million in Salaries?
I'd much rather stick to my Blue Chip Portfolio in which my Dividends pay higher than most people make in a Year. You can say I made a Bet on pmn and I was in the wrong.

<< Previous

Bullboard Posts

Next >>

Options trading in a volatile macro environment